Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Colorcon
Moodys
Medtronic
Baxter

Last Updated: May 28, 2022

Investigational Drug Information for Fasudil


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Fasudil?

Fasudil is an investigational drug.

There have been 14 clinical trials for Fasudil. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2019.

The most common disease conditions in clinical trials are Motor Neuron Disease, Amyotrophic Lateral Sclerosis, and Sclerosis. The leading clinical trial sponsors are Shahid Beheshti University of Medical Sciences, Woolsey Pharmaceuticals, and Brigham and Women's Hospital.

There are five hundred and fifty-three US patents protecting this investigational drug and ten international patents.

Recent Clinical Trials for Fasudil
TitleSponsorPhase
Rho Kinase Inhibitor in Amyotrophic Lateral SclerosisWoolsey PharmaceuticalsPhase 2
Rho Kinase (ROCK) Inhibitor in Tauopathies - 1Woolsey PharmaceuticalsPhase 2
Fasudil fOr redUcing elopemeNt and Spatial DisorientationWoolsey PharmaceuticalsPhase 2

See all Fasudil clinical trials

Clinical Trial Summary for Fasudil

Top disease conditions for Fasudil
Top clinical trial sponsors for Fasudil

See all Fasudil clinical trials

US Patents for Fasudil

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Fasudil See Plans and Pricing Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof The Regents of the University of California (Oakland, CA) See Plans and Pricing
Fasudil See Plans and Pricing Minimal volume reprogramming of mononuclear cells Fate Therapeutics, Inc. (San Diego, CA) See Plans and Pricing
Fasudil See Plans and Pricing SC-.beta. cells and compositions and methods for generating the same President and Fellows of Harvard College (Boston, MA) See Plans and Pricing
Fasudil See Plans and Pricing Six-membered C--N-bonded aryl sulphide and aryl sulphoxide derivatives as pesticides BAYER CROPSCIENCE AKTIENGESELLSCHAFT (Monheim am Rhein, DE) See Plans and Pricing
Fasudil See Plans and Pricing Use of neural cells derived from human pluripotent stem cells for the treatment of neurodegenerative diseases International Stem Cell Corporation (Carlsbad, CA) See Plans and Pricing
Fasudil See Plans and Pricing sGC stimulators Ironwood Pharmaceuticals, Inc. (Cambridge, MA) See Plans and Pricing
Fasudil See Plans and Pricing 5-aminotetrahydroquinoline-2-carboxylic acids and their use BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Fasudil

Drugname Country Document Number Estimated Expiration Related US Patent
Fasudil European Patent Office EP2981556 2033-04-02 See Plans and Pricing
Fasudil World Intellectual Property Organization (WIPO) WO2014165513 2033-04-02 See Plans and Pricing
Fasudil Australia AU2015286634 2034-07-11 See Plans and Pricing
Fasudil Brazil BR112017000398 2034-07-11 See Plans and Pricing
Fasudil China CN106659720 2034-07-11 See Plans and Pricing
Fasudil European Patent Office EP3177291 2034-07-11 See Plans and Pricing
Fasudil Japan JP2017519802 2034-07-11 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Colorcon
Moodys
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.